Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution

NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in value-based sleep health solutions, to bring the comprehensive care program to payers nationwide. The collaboration leverages the strengths of both companies to deliver a tiered, data-driven solution for improving member health outcomes, reducing healthcare costs, and enhancing productivity through the integration of behavioral health, sleep, and cardiometabolic care. The collaboration targets the $150 billion sleep apnea market affecting over 29 million Americans, with up to 80% of moderate to severe cases currently undiagnosed¹.

This collaboration unites Dario's clinically validated cardiometabolic and behavioral artificial intelligence ('AI')-powered health solutions with GreenKey's 'sleep-first' approach to obstructive sleep apnea ('OSA') management. Together, the organizations aim to drive awareness, and secure payer contracts, through a robust multi-channel marketing plan designed to engage Commercial, ASO ('Administrative Services Only'), Medicaid, and Medicare Advantage plans, as well as self-funded employers, consultants, brokers, and value-based care providers.

The immediate joint launch of the collaboration will focus on engaging large payers as strategic channel collaborators while building a national network of aligned service providers. The strategic initiatives will utilize a mix of targeted outreach, thought leadership, and high-impact content to connect with decision-makers and advance adoption of this innovative, value-based care model.

OSA affects over 29 million Americans, with up to 80% of moderate to severe cases undiagnosed, driving more than $150 billion in annual U.S. costs due to associated cardiometabolic and behavioral comorbidities like diabetes, obesity, hypertension, and depression². As payers increasingly shift toward value-based care, there is a growing need for integrated solutions that address these interconnected conditions. Combining GreenKey's sleep-first approach with Dario's proven cardiometabolic and behavioral health programs delivers a holistic, data-driven solution that improves clinical outcomes, reduces healthcare costs, and meets the market demand for comprehensive, high-return on investment ('ROI') chronic condition management.

"We believe that this agreement marks a pivotal step forward in reshaping how chronic conditions like sleep apnea and cardiometabolic disorders are addressed in tandem," said Steven Nelson, Chief Commercial Officer at Dario. "By combining our real-time engagement and data-driven platform with GreenKey's powerful OSA cost-saving engine, we are offering payers a differentiated, value-based care solution that not only improves health outcomes but significantly reduces the total cost of care. This collaboration opens access to a multi-billion-dollar market and aligns perfectly with our mission to provide integrated, data-driven solutions for the most prevalent and costly chronic conditions facing healthcare today."

This joint solution is a comprehensive, tiered program that delivers:

• Improved Member Outcomes through enhanced sleep health, optimized GLP-1 utilization, and effective comorbidity management
• Reduced Healthcare Costs with decreased Emergency Department and inpatient utilization
• Increased Productivity from better sleep and overall health
• Actionable Data Insights to continuously optimize program performance

Studies have shown that even weight loss of 10% can lead to a substantial reduction in apnea–hypopnea index ('AHI'), indicating a decrease in the severity of sleep apnea. AHI is a simple measure of how often during sleep someone either completely stops breathing or breathes much more shallowly. "We are excited to collaborate with Dario, a proven leader in digital health engagement and outcomes," said Michael Markus, Chief Executive Officer of GreenKey Health. "Our collaboration offers payers a unique opportunity to activate a clinically integrated funnel that identifies the right patients for the right programs—starting with sleep and extending through behavior and cardiometabolic health. This is how we redefine chronic care for the modern healthcare system."

By aligning behavioral health and sleep-first strategies with precision cardiometabolic interventions, the Dario-GreenKey collaboration provides a superior offering that meets the growing demand for integrated, measurable chronic care solutions.

^1,2 https://aasm.org/economic-burden-of-undiagnosed-sleep-apnea-in-u-s-is-nearly-150b-per-year/?utm_source=chatgpt.com  

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

About GreenKey Health

GreenKey Health is a pioneering healthcare company focused on addressing obstructive sleep apnea through value-based care. Its GreenKey4Life platform empowers payers to improve outcomes, reduce costs, and unlock productivity gains through an integrated, sleep-first approach to chronic condition management.

For more information, visit www.greenkey.health. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the benefits of the collaboration between the Company and GreenKey; that the collaboration intends to engage large payers and build a national service provider network; that the collaboration will improve outcomes, reduce costs, and meet market demand; that the collaboration opens access to a multi-billion-dollar market; and that the collaboration will provide a solution to meet growing demand for measurable, integrated care. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Mary Mooney
VP Marketing
+1-312-593-4280

DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
[email protected]
+315-378-6922
GreenKey Health Communications
[email protected]

Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

SOURCE DarioHealth Corp.